ALK4290

DRUG2 trials

Sponsors

Alkahest, Inc.

Conditions

Wet Age-related Macular Degeneration

Phase 2

Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration

CompletedNCT03558061

Alkahest, Inc.Wet Age-related Macular Degeneration

Start: 2018-04-04End: 2018-11-18Updated: 2020-12-16

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

CompletedNCT03558074

Alkahest, Inc.Wet Age-related Macular Degeneration

Start: 2018-04-20End: 2018-11-29Updated: 2020-12-22